Eligibility Criteria Inclusion criteria: Full-text original articles
Orforglipron , an oral GLP-1 agonist, has shown the ability to maintain weight loss in patients switching from injectable therapies
Quem no pode usar Embora a retatrutida ainda no possua uma bula oficial com as contraindicaes definitivas, este medicamento no deve ser usado, atualmente, fora de ensaios clnicos oficiais
However, no controlled conditions (placebo effects, natural healing, concurrent treatments confound results)
And concessions granted in recent deals with the Trump administration to make the drugs more readily available through Medicare and Medicaid are insufficient to widen access
In conclusion, BARI-STEP, a randomized, placebo-controlled trial investigating the use of once-weekly semaglutide 2.4 mg in a post-bariatric patient population with a suboptimal clinical response, demonstrates that semaglutide 2.4 mg in patients with a suboptimal clinical response results in substantial, clinically relevant body weight reduction, and improvements in metabolic health and quality of life